Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Lake Street Maintains Buy on Augmedix, Lowers Price Target to $3.5

Author: Benzinga Newsdesk | May 14, 2024 01:17pm
Lake Street analyst Brooks O'Neil maintains Augmedix (NASDAQ:AUGX) with a Buy and lowers the price target from $8 to $3.5.

Posted In: AUGX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist